rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
2B
|
pubmed:dateCreated |
2001-6-8
|
pubmed:abstractText |
The efficacy and toxicity of the combination of two cytotoxic compounds that are active as single agents in non-small cell lung cancer (NSCLC), paclitaxel (Taxol) and carboplatin (Paraplatin) was investigated in a multicenter, community-based setting.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0250-7005
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
21
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1487-94
|
pubmed:dateRevised |
2006-4-24
|
pubmed:meshHeading |
pubmed-meshheading:11396237-Adenocarcinoma,
pubmed-meshheading:11396237-Aged,
pubmed-meshheading:11396237-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:11396237-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11396237-Carboplatin,
pubmed-meshheading:11396237-Carcinoma, Large Cell,
pubmed-meshheading:11396237-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:11396237-Carcinoma, Squamous Cell,
pubmed-meshheading:11396237-Cohort Studies,
pubmed-meshheading:11396237-Dose-Response Relationship, Drug,
pubmed-meshheading:11396237-Female,
pubmed-meshheading:11396237-Follow-Up Studies,
pubmed-meshheading:11396237-Humans,
pubmed-meshheading:11396237-Lung Neoplasms,
pubmed-meshheading:11396237-Male,
pubmed-meshheading:11396237-Middle Aged,
pubmed-meshheading:11396237-Neoplasm Metastasis,
pubmed-meshheading:11396237-Paclitaxel,
pubmed-meshheading:11396237-Survival Rate,
pubmed-meshheading:11396237-Time Factors,
pubmed-meshheading:11396237-Treatment Outcome
|
pubmed:articleTitle |
Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
|
pubmed:affiliation |
Clinique du Sud-Luxembourg (Site St.-Joseph), Arlon, Belgium.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study
|